The following is an article about possible
concerns regarding Chantix side effects circulated by Reuters:
WASHINGTON (Reuters) 2/1/08 - U.S. regulators on
Friday said Pfizer Inc's anti-smoking drug Chantix appears
increasingly likely to be linked to serious psychiatric
behavior, and called for stronger label warnings.
The Food and Drug Administration said
after an analysis of reports of suicidal thoughts and behavior
potentially linked to the medication, it was calling for Pfizer
to strengthen the label warnings on the drug.
FDA said the drug is effective but that
patients should talk to their doctors about this new safety
The drug has been prescribed to about 4
million people in the United States since approval in 2006,
according to Pfizer.
Chantix is one of the most recent
non-nicotine stop-smoking treatments on the market. It was
approved by the FDA in 2006. After its launch, some of the more
than 5 million patients who used the drug began to report
adverse side events, including anxiety, other serious
psychiatric changes, and "vivid" and "unusual" dreams. Because
of these reports, Pfizer has strengthened the warning label for
Chantix. Last week's FDA announcement formalized more specific
safety warnings for the drug's label.
Chantix's biggest advantages against
Nicoderm and most other smoking-cessation agents is that it
contains no addictive nicotine, which is currently the
predominant "solution" for smoking cessation on the market.
There has been no reporting about chantix drug interaction with
other pharmaceuticals, beyond what is already known in the
In a 2007 year ending conference call,
Pfizer's executives did not disclose what amount of the
potential market for Chantix has a psychiatric illness that
would prevent it from using Chantix. According to experts,
Chantix is Pfizer's most important new drug at the moment. Sales
of the drug have grown much faster than experts have expected.
Growing 312% year over year to $280 million worldwide.